Saturday 17 October 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.1% and free cash flow fell 19.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.28
0.09
−24.32%
Follow MBRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.39 | 1.41 | 1.38 | 0.94 |
Net Debt/EBITDA |
1.14 | 1.18 | 1.31 | 0.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | (0.35) | 0.42 | 0.84 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.55 | 0.50 | 0.48 | 0.53 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(4.84) | (4.53) | (1.48) | (1.17) | |
Cash per Share |
4.49 | 7.49 | 2.50 | 1.28 | |
Shareholders Equity per Share |
(18.04) | 12.67 | 3.68 | 2.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(18.04) | 12.67 | 3.68 | 2.04 | |
Free Cash Flow |
(7.22) | (5.37) | (6.11) | (6.66) | |
Working Capital |
2.20 | 2.83 | 3.00 | (0.59) | |
Net Current Asset Value |
(39.39) | 2.57 | 2.78 | (0.78) | |
| Other line items | |||||
Quick Ratio |
1.18 | 1.30 | 1.30 | 0.78 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.84) | (4.53) | (1.48) | (1.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.64 | 6.11 | 7.43 | 8.61 | |
Average Assets |
21.87 | 19.53 | 22.19 | 21.34 | |
Average Common Equity |
(9.72) | 13.11 | 7.61 | 2.21 |
Columns are period end dates